BEMORADAN

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H13N3O3
Molecular Weight	259.2606
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1CC(=O)NN=C1C2=CC=C3NC(=O)COC3=C2

InChI

InChIKey=XZPGINPFWXLYNW-UHFFFAOYSA-N

InChI=1S/C13H13N3O3/c1-7-4-11(17)15-16-13(7)8-2-3-9-10(5-8)19-6-12(18)14-9/h2-3,5,7H,4,6H2,1H3,(H,14,18)(H,15,17)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2153210

Bemoradan (RWJ-22867), a potent positive inotropic agent, inhibits cardiac phosphodiesterase fraction III. This compound was developed for the management of congestive heart failure. However, the information about the nowadays study of bemoradan is not available.

Originator

Approval Year

PubMed

Title	Date	PubMed
Evaluation of the excretion, and metabolism of the cardiotonic agent bemoradan in male rats and female beagle dogs.	2002-01-26	11808869
Pharmacokinetics and bioavailability of bemoradan, a long-acting inodilator in healthy males.	1994-02	8004360
Simultaneous monitoring of bemoradan pharmacokinetics and hemodynamics in mongrel dogs.	1992-10	1489944
Heteroatom analogues of bemoradan: chemistry and cardiotonic activity of 1,4-benzothiazinylpyridazinones.	1992-01	1732525

Patents

Sample Use Guides

In Vivo Use Guide

bemoradan HCL salt in capsules. 0.5, 1, 1.5 and 2 mg of bemoradan

Route of Administration: Oral

Name

Type

Language

ORF 22867

Preferred Name

English

BEMORADAN

Official Name

English

7-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)-2H-1,4-benzoxazin-3(4H)-one

Systematic Name

English

2H-1,4-BENZOXAZIN-3(4H)-ONE, 7-(1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL)-

Systematic Name

English

BEMORADAN [USAN]

Common Name

English

bemoradan [INN]

Common Name

English

ORF-22867

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C744